Skip to content
TrialMatch
Sign up
Recruiting Phase 3

Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients

Create a profile to match View the full record on ClinicalTrials.gov

About this study

To evaluate: The radiographic progression-free survival (rPFS) of metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with androgen deprivation therapy (ADT) + second-generation antiandrogens±chemotherapy combined with cytoreductive prostatectomy (CRP)

Condition
Metastatic Prostate Cancer, Therapy, Directly Observed
Tested
Cytoreductive prostatectomy or brachytherapy, ADT+second-generation antiandrogens ± chemotherapy
Sponsor
The First Affiliated Hospital with Nanjing Medical University

Who can join

Age
18 to 75 years
Sex
Male only
Healthy volunteers
Not accepted

Inclusion 10

  • Minimum age: 18 years
  • Maximum age: 75 years
  • Eligible sex: Male
  • Study condition: Metastatic Prostate Cancer, Therapy, Directly Observed
  • Male aged ≥18 and ≤75;
  • Histologically confirmed prostate adenocarcinoma;
  • Evidence of metastasis confirmed by magnetic resonance imaging (MRI)/computed tomography (CT) scan, bone scan, or histology;
  • Clinical stage M1a (distant lymph node positive), M1b (bone metastasis), or M1c (visceral organ metastasis);
  • Prostate cancer has not received local treatment (e.g., prostate radiotherapy, cryotherapy, etc.);
  • The surgeon believes the prostate can be removed;

Exclusion 7

  • The surgeon believes the disease is unresectable;
  • Life expectancy less than 2 years;
  • Active spinal cord compression;
  • History of prior local treatment for prostate cancer;
  • Difficulty swallowing, chronic diarrhea, intestinal obstruction, and other factors affecting drug intake and absorption;
  • Refusal to sign the informed consent;
  • Investigator believes the individual is not suitable for inclusion.

Where

1 site, 1 recruiting

The First Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, China

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.